CompletedNot Applicable

The Incidence and Risk of Vein Infusion Phlebitis After Intravenous Infusion of Proton Pump Inhibitors

France200 participantsStarted 2020-12-04

Plain-language summary

Intermittent or continuous proton pump inhibitor (PPI) therapy are recommended for high-risk bleeding ulcers according to the French Society of Gastroenterology. The prevalence of incidence of vein infusion phlebitis after PPI intravenous infusion is high in geriatric acute ward (about 10% of severe vein infusion phlebitis). The primary of objective of the study is to determinate the prevalence of vein infusion phlebitis after PPI intravenous infusion in aging people. The secondary of objective of the study if to determinate the factors of risk of vein infusion phlebitis.

Who can participate

Age range70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged \> 70 years; * Undergo intravenous continuous or intermittent proton pump inhibitor therapy; * Patients being informed and not opposed to the study. Exclusion Criteria: * Existing vein infusion phlebitis before the PPI infusion by intravenous route; * Under guardianship or curators; * Covered by french AME health system.

What they're measuring

Occurence of infusion phlebitis

Timeframe: at day-5

Trial details

NCT IDNCT04658758

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-11-30

View on ClinicalTrials.gov More Vein Infusion Phlebitis trials